| HOME >> BIOLOGY >> TECHNOLOGY |
"It is highly likely that all subsequent members of the CCR5 antagonist drug class will necessitate a tropism test prior to prescribing," said Sylvia Eash, Ph.D., analyst at Decision Resources. "To expand the use of their drugs and overcome this substantial hurdle to wider uptake, marketers of CCR5 antagonist drugs should actively support the development of a low cost test that delivers fast and accurate results."
Novel HIV Therapies: Physician and Payer Perspective on Recently Launched and Emerging Antiretrovirals is based on a U.S. survey of 103 infectious disease specialists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
About Physician & Payer Forum
Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources
781-296-2563
| SOURCE Decision Resources Copyright©2008 PR Newswire. All rights reserved |